January 18th, 2006
Micromet Closes Four Additional License Agreements for Single-chain Antibodies
January 18, 2006 – Munich, Germany – Micromet AG has granted access to single-chain antibody (SCA) technology under its exclusive marketing agreement with Enzon Pharmaceuticals, Inc. to Abbott, Alligator Bioscience AB, Haptogen Ltd. and an undisclosed biopharmaceutical company.
Abbott, Alligator Bioscience AB and Haptogen Ltd. received research licenses and an undisclosed biopharmaceutical company received a product license for the development and commercialization of an SCA product for the treatment of cancer.
"Since the start of our licensing program for SCA technology, we have executed twelve license agreements on behalf of Micromet and Enzon, demonstrating the strong demand and outstanding potential of SCAs for multiple applications in research and therapeutics", comments Christian Itin, CEO of Micromet.
In April 2002, Micromet and Enzon combined their respective single-chain antibody (SCA) patent portfolios into the largest coherent IP estate in the field of SCA covering the core technology relevant for all SCAs being commercially developed today. Micromet is the exclusive SCA marketing partner for third party licensing. Proceeds from the marketing are shared with Enzon. |
